Abstract:Background: Tumor immunotherapy has shown promising efficacy in various types of cancer. However, the effectiveness of immunotherapy is often limited by the immune-suppressive microenvironment within tumors. To address this challenge, we developed a method of intratumoral injection using lipid nanoparticles (LNPs) to deliver Toll-like receptor 7, 8, and 9 agonists. LNPs effectively enhance immune activation while reducing systemic responses by increasing drug retention within the tumor. Methods: We encapsulated 30nt-CpG and Resiquimod into LNPs (QTsomeTM). Subcutaneous inoculation of 2 × 106 MC38 cells was performed in mice. Once the average tumor volume reached approximately 100mm3, we divided 15 mice into 3 groups based on tumor volume. Intratumoral injections began on the same day of grouping, with a dosage of 1mg/kg (5 injections every 3 days). Tumor volume and body weight were measured twice a week. We conducted two parallel experiments, each with 7 mice for the MC38 model and 8 mice for the B16 melanoma model in each group, to compare the efficacy of 26nt-CpG and 30nt-CpG. Results: On the 15th day post-dosing, the tumor growth inhibition rate (TGI) was 79.9% (P<0.001), resulting in a 73.7% increase in survival rate. LNP-delivered 26nt-CpG demonstrated a TGI rate of 75.4% (P<0.001), while 30nt-CpG showed a TGI of 81.9% (P<0.001). Interestingly, the 26nt-CpG group exhibited faster weight gain, indicating better safety. In the mouse B16 melanoma model, LNP-delivered 26nt-CpG achieved a TGI rate of 75.2% (P<0.001), slightly higher than 30nt-CpG (71.0%, P<0.001), and also resulted in faster weight gain. Conclusion: In conclusion, the use of LNP-delivered Toll-like receptor agonists demonstrated excellent tumor therapeutic effects and good safety in mouse models. Activation of Toll-like receptors effectively stimulated immune cells such as CD8+ T cells and NK cells, enhancing their ability to kill tumor cells. Direct injection of LNPs into the tumor improved this effect while reducing systemic side effects. This drug holds promise as a broad-spectrum anti-tumor treatment and may have potential for expanding the indications of existing tumor immunotherapies. Citation Format: Jun Bai, Fei Su, Chen Li, Yujing Wu, Jing Li, Xiaobin Zhao, Yongsheng Yang, Robert J Lee. Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr B049.

The novel selective TLR7 agonist GY101 suppresses colon cancer growth by stimulating immune cells

A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer

TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes

Oncolytic adenovirus H101 enhanced antitumor effects of PD-1 blockade by downregulating CD47 on tumor cells

Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer.

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy

Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Lactobacillus rhamnosus GG re-shapes gut microbiota and triggers STING-type I IFN-dependent antitumor immunity

The TLR7 Agonist Induces Tumor Regression Both by Promoting CD4+T Cells Proliferation and by Reversing T Regulatory Cell-Mediated Suppression Via Dendritic Cells

Experimental Therapy for Colon Cancer: Anti-Cancer Effects of TLR9 Agonism, Combination with Other Therapeutic Modalities, and Dependence Upon P53.

Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor

TLR7/8 Agonists Promote NK–DC Cross-Talk to Enhance NK Cell Anti-Tumor Effects in Hepatocellular Carcinoma

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Tlr1/Tlr2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment

Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma

Application potential of toll-like receptors in cancer immunotherapy: Systematic review.

Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer

Abstract B049: Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy

A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer

RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer